β-Cell-Derived Extracellular Vesicles Boost β-Cell Functionality in Human Pancreatic Islets.

Area of Science:

• Nanomedicine
• Cell Biology
• Endocrinology

Background:

• Extracellular vesicles (EVs) are promising nanomedicine therapeutics due to their biological origin and cargo.
• Understanding EV effects in 2D vs. 3D diabetes models is crucial for therapeutic development.
• Previous research has not fully explored the impact of beta-cell-derived EVs on beta-cell function.

Purpose of the Study:

• To investigate the therapeutic potential of beta-cell-derived EVs in enhancing beta-cell function and insulin secretion.
• To compare the effects of EVs in 2D and 3D diabetes models, specifically human EndoC-βH1-derived spheroids and human donor pancreatic islets.
• To explore the underlying molecular mechanisms of EV-mediated improvements in beta-cell function.

Main Methods:

• Isolation and characterization of EVs from the human EndoC-βH1 beta-cell line.
• Assessment of EV uptake in EndoC-βH1 spheroids and human islets using confocal microscopy.
• Evaluation of insulin secretion via glucose-stimulated insulin secretion (GSIS) tests and ELISA.
• Analysis of beta-cell gene expression using quantitative polymerase chain reaction (qPCR).
• Proteomic analysis to identify key proteins involved in beta-cell function.

Main Results:

• EV treatment significantly increased insulin production in both spheroids and human islets.
• In spheroids, qPCR showed elevated expression of PDX1 and SUR1 genes.
• EV-treated human islets demonstrated a 3-fold increase in insulin secretion without significant changes in key beta-cell genes.
• Proteomic analysis revealed enrichment of proteins crucial for beta-cell function and survival in EV-treated samples.

Conclusions:

• Beta-cell-derived EVs effectively promote beta-cell functionality in vitro by up-regulating genes involved in insulin secretion.
• The EndoC-βH1 spheroid model serves as a valuable platform for preclinical EV therapy development.
• EVs show significant potential for enhancing islet transplantation outcomes in type 1 diabetes patients.